Cyclerion Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Peter M. Hecht amends Schedule 13D, reporting a beneficial ownership of 910,240 shares of Cyclerion Therapeutics' common stock, representing 19.4% of the class.
NASDAQ
Peter M. Hecht, a significant shareholder, increased his beneficial ownership in Cyclerion Therapeutics, Inc. to 27.9% through a recent private placement of common stock.